Novel small-molecule inhibitors of arylamine N-acetyltransferases: Drug discovery by high throughput screening

Combinatorial Chemistry and High Throughput Screening

Volumn 14, Issue 2, 2011, Pages 117-124

  Westwood, Isaac M ^a   Kawamura, Akane ^a   Russell, Angela J ^a   Sandy, James ^a   Davies, Stephen G ^a   Sim, Edith ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Arylamine N acetyltransferases; Drug discovery; High throughput screening; NATs

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ESTROGEN;

ARTICLE; BACTERIAL CELL; BIOSYNTHESIS; BREAST CANCER; CELL WALL; DRUG DESIGN; DRUG SCREENING; MACROPHAGE; MYCOBACTERIUM; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; BACTERIA; BACTERIAL INFECTIONS; BREAST NEOPLASMS; CRICETINAE; DRUG DISCOVERY; ENZYME INHIBITORS; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; SMALL MOLECULE LIBRARIES;

CORYNEBACTERINEAE; EUKARYOTA; PROKARYOTA;

EID: 79751516366     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/138620711794474051     Document Type: Article

References (42)

1. Stratmann A.; Toupet C.; Schilling W.; Traber R.; Oberer L.; Schupp T. Intermediates of rifamycin polyketide synthase produced by an Amycolatopsis mediterranei mutant with inactivated rifF gene. Microbiology 1999 145 3365-3375. (Pubitemid 30018781)
2. Pompeo F.; Mushtaq A.; Sim E. Expression and purification of the rifamycin amide synthase RifF an enzyme homologous to the prokaryotic arylamine N-acetyltransferases. Protein Expr. Purif. 2002 24 138-151. (Pubitemid 34805421)
3. Bhakta S.; Besra G.S.; Upton A.M.; Parish T.; Sholto-Douglas- Vernon C.; Gibson K.J.C.; Knutton S.; Gordon S.; daSilva R.P.; Anderton M.C.; Sim E. Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target. J. Exp. Med. 2004 199 1191-1199. (Pubitemid 38620256)
4. Sinclair J.C.; Delgoda R.; Noble M.E.; Jarmin S.; Goh N.K.; Sim E. Purification characterization and crystallization of an Nhydroxyarylamine O-acetyltransferase from Salmonella typhimurium. Protein Expr. Purif. 1998 12 371-380. (Pubitemid 28360432)
5. Payton M.; Auty R.; Delgoda R.; Everett M.; Sim E. Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: increased expression results in isoniazid resistance. J. Bacteriol. 1999 181 1343-1347. (Pubitemid 29119577)
6. Westwood I.M.; Holton S.J.; Rodrigues-Lima F.; Dupret J.M.; Bhakta S.; Noble M.E.; Sim E. Expression purification characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase. Biochem. J. 2005 385 605-612. (Pubitemid 40165095)
7. Sinclair J.C.; Sandy J.; Delgoda R.; Sim E.; Noble M.E. Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nat. Struct. Biol. 2000 7 560-564. (Pubitemid 30445912)
8. Sandy J.; Mushtaq A.; Kawamura A.; Sinclair J.; Sim E.; Noble M. The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis - an enzyme which inactivates the antitubercular drug isoniazid. J. Mol. Biol. 2002 318 1071-1083. (Pubitemid 35007369)
9. Cheon H.G.; Hanna P.E. Effect of group-selective modification reagents on arylamine N-acetyltransferase activities. Biochem. Pharmacol. 1992 43 2255-2268.
10. Delomenie C.; Goodfellow G.H.; Krishnamoorthy R.; Grant D.M.; Dupret J.M. Study of the role of the highly conserved residues Arg(9) and Arg(64) in the catalytic function of human Nacetyltransferases NAT1 and NAT2 by site-directed mutagenesis. Biochem. J. 1997 323 207-215.
11. Sandy J.; Mushtaq A.; Holton S.J.; Schartau P.; Noble M.E.; Sim E. Investigation of the catalytic triad of arylamine Nacetyltransferases: essential residues required for acetyl transfer to arylamines. Biochem. J. 2005 390 115-123. (Pubitemid 41192237)
12. Watanabe M.; Sofuni T.; Nohmi T. Involvement of Cys69 residue in the catalytic mechanism of N-hydroxyarylamine Oacetyltransferase of Salmonella typhimurium. Sequence similarity at the amino acid level suggests a common catalytic mechanism of acetyltransferase for S. typhimurium and higher organisms. J. Biol. Chem. 1992 267 8429-8436.
13. Holton S.J.; Dairou J.; Sandy J.; Rodrigues-Lima F.; Dupret J.M.; Noble M.; Sim E. Structure of Mesorhizobium loti arylamine N-acetyltransferase 1. Acta. Crystallogr. F. 2005 61 14-16. (Pubitemid 44210969)
14. Fullam E.; Westwood I.M.; Anderton M.C.; Lowe E.D.; Sim E.; Noble M.E. Divergence of co-factor recognition across evolution: coenzyme a binding in a prokaryotic arylamine N-acetyltransferase. J. Mol. Biol. 2008 375 178-191. (Pubitemid 350160690)
15. Sandy J.; Holton S.; Fullam E.; Sim E.; Noble M. Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis. Protein Sci. 2005 14 775-782. (Pubitemid 40283916)
16. Westwood I.M.; Sim E. Kinetic characterisation of arylamine Nacetyltransferase from Pseudomonas aeruginosa. BMC Biochem. 2007 8 3.
17. Riddle B Jencks WP: Acetyl-coenzyme A: arylamine Nacetyltransferase. Role of the acetyl-enzyme intermediate and the effects of substituents on the rate. J. Biol. Chem. 1971 246 3250-3258.
18. Andres H.H.; Kolb H.J.; Schreiber R.J.; Weiss L. Characterization of the active site substrate specificity and kinetic properties of acetyl-CoA:arylamine N-acetyltransferase from pigeon liver. Biochim. Biophys. Acta. 1983 746 193-201.
19. Sim E.; Westwood I.; Fullam E. Arylamine N-acetyltransferases. Expert Opin. Drug Metab. Toxicol. 2007 3 169-184. (Pubitemid 47316039)
20. Kawamura A.; Westwood I.M.; Wakefield L.; Long H.; Zhang N.; Walters K.J.; Redfield C.; Sim E. Mouse N-acetyltransferase type 2 the homologue of human N-acetyltransferase type 1. Biochem. Pharmacol. 2008 75 1550-1560.
21. Kelly S.L.; Sim E. Arylamine N-acetyltransferase in Balb/c mice: identification of a novel mouse isoenzyme by cloning and expression in vitro. Biochem. J. 1994 302 347-353. (Pubitemid 24280084)
22. Walraven J.M.; Barker D.F.; Doll M.A.; Hein D.W. Tissue expression and genomic sequences of rat N-acetyltransferases rNat1 rNat2 rNat3 and Functional characterization of a novel rNat3*2 genetic variant. Toxicol. Sci. 2007 99 413-421. (Pubitemid 351753059)
23. Minchin R.F. Acetylation of p-aminobenzoylglutamate a folic acid catabolite by recombinant human arylamine Nacetyltransferase and U937 cells. Biochem. J. 1995 307 1-3.
24. Hein D.W.; Boukouvala S.; Grant D.M.; Minchin R.F.; Sim E. Changes in consensus arylamine N-acetyltransferase (NAT) gene nomenclature. Pharmacogenet. Genom. 2008 18 367-368. (Pubitemid 351367530)
25. Wakefield L.; Cornish V.; Long H.; Griffiths W.J.; Sim E. Deletion of a xenobiotic metabolizing gene in mice affects folate metabolism. Biochem. Biophys. Res. Commun. 2007 364 556-560. (Pubitemid 350030921)
26. Wakefield L.; Robinson J.; Long H.; Ibbitt J.C.; Cooke S.; Hurst H.C.; Sim E. Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: A potential marker in estrogen receptorpositive tumors. Genes Chromosomes Cancer 2008 47 118-126.
27. Adam P.J.; Berry J.; Loader J.A.; Tyson K.L.; Craggs G.; Smith P.; De Belin J.; Steers G.; Pezzella F.; Sachsenmeir K.F.; Stamps A.C.; Herath A.; Sim E.; O'Hare M.J.; Harris A.L.; Terrett J.A. Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol. Cancer Res. 2003 1 826-835. (Pubitemid 37174454)
28. Wang H.; Vath G.M.; Gleason K.J.; Hanna P.E.; Wagner C.R.; Probing the mechanism of hamster arylamine N-acetyltransferase 2 acetylation by active site modification site-directed mutagenesis and pre-steady state and steady state kinetic studies. Biochemistry 2004 43 8234-8246. (Pubitemid 38808279)
29. Wang H.; Liu L.; Hanna P.E.; Wagner C.R. Catalytic mechanism of hamster arylamine N-acetyltransferase 2. Biochemistry 2005 44 15295-15306.
30. Kawamura A.; Graham J.; Mushtaq A.; Tsiftsoglou S.A.; Vath G.M.; Hanna P.E.; Wagner C.R.; Sim E. Eukaryotic arylamine Nacetyltransferase. Investigation of substrate specificity by high throughput screening. Biochem. Pharmacol. 2005 69 347-359. (Pubitemid 41556581)
31. Wang H.; Vath G.M.; Kawamura A.; Bates C.A.; Sim E.; Hanna P.E.; Wagner C.R. Over-expression purification and characterization of recombinant human arylamine Nacetyltransferase 1. Protein J. 2005 24 65-77. (Pubitemid 40875246)
32. Brooke E.W.; Davies S.G.; Mulvaney A.W.; Pompeo F.; Sim E.; Vickers R.J. An approach to identifying novel substrates of bacterial arylamine N-acetyltransferases. Bioorg. Med. Chem. 2003 11 1227-1234. (Pubitemid 36293519)
33. Brideau C.; Gunter B.; Pikounis B.; Liaw A. Improved statistical methods for hit selection in high throughput screening. J. Biomol. Screen. 2003 8 634-647.
34. Lipinski C.A.; Lombardo F.; Dominy B.W.; Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001 46 3-26. (Pubitemid 33653411)
35. Mushtaq A.; Payton M.; Sim E. The COOH terminus of arylamine N-acetyltransferase from Salmonella typhimurium controls enzymic activity. J. Biol. Chem. 2002 277 12175-12181. (Pubitemid 34952783)
36. Westwood I.M.; Bhakta S.; Russell A.; Fullam E.; Anderton M.; Kawamura A.; Mulvaney A.; Vickers R.; Boeruth V.; Besra G.; Davies S.G.; Sim E.; Identification of arylamine Nacetyltransferase inhibitors as an approach towards novel antituberculars. Protein Cell 2010 1 82-95.
37. Brooke E.W.; Davies S.G.; Mulvaney A.W.; Okada M.; Pompeo F.; Sim E.; Vickers R.J.; Westwood I.M. Synthesis and in vitro evaluation of novel small molecule inhibitors of bacterial arylamine N-acetyltransferases (NATs). Bioorg. Med. Chem. Lett. 2003 13 2527-2530. (Pubitemid 36830765)
38. Boukouvala S.; Fakis G. Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metab. Rev. 2005 37 511-564. (Pubitemid 41434161)
39. Zhang N.; Liu L.; Liu F.; Wagner C.R.; Hanna P.E.; Walters K.J. NMR-based model reveals the structural determinants of mammalian arylamine N-acetyltransferase substrate specificity. J. Mol. Biol. 2006 363 188-200. (Pubitemid 44414850)
40. Wu H.; Dombrovsky L.; Tempel W.; Martin F.; Loppnau P.; Goodfellow G.H.; Grant D.M.; Plotnikov A.N. Structural basis of substrate-binding specificity of human arylamine Nacetyltransferases. J. Biol. Chem. 2007 282 30189-30197. (Pubitemid 350035257)
41. Laurieri N.; Crawford M.H.J. Kawamura A.; Westwood I.M.; Robinson J.; Fletcher A.M.; Davies S.G.; Sim E.; Russell A.J. Small molecule colorimetric probes for specific detection of human arylamine N-acetyltransferase 1 a potential breast cancer biomarker. J. Am. Chem. Soc. 2010 132 3238-3239.
42. Ballester P.J.; Westwood I.; Laurieri N.; Sim E.; Richards W.G. Prospective virtual screening with ultrafast shape recognition: the identification of novel inhibitors of arylamine N-acetyltransferases. J. R. Soc. Interface 2010 doi:10.1098/rsif.2009.0170 1-8.